Trulieve Cannabis Corp. (OTCMKTS:TCNNF) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 99,700 shares, a growth of 56.3% from the March 15th total of 63,800 shares. Based on an average trading volume of 579,800 shares, the days-to-cover ratio is currently 0.2 days.
Trulieve Cannabis stock opened at $39.85 on Friday. Trulieve Cannabis has a one year low of $8.47 and a one year high of $53.73. The business’s fifty day moving average is $46.38 and its 200 day moving average is $36.08.
Several equities analysts have recently weighed in on the company. Alliance Global Partners raised their price target on Trulieve Cannabis to $66.00 and gave the company a “buy” rating in a report on Tuesday, January 26th. Stifel Nicolaus raised their price target on Trulieve Cannabis from $107.00 to $118.00 and gave the company a “buy” rating in a report on Thursday, March 25th. Roth Capital assumed coverage on Trulieve Cannabis in a report on Thursday, February 4th. They set a “buy” rating and a $60.00 price target for the company. Canaccord Genuity raised their price target on Trulieve Cannabis from $87.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Cowen assumed coverage on Trulieve Cannabis in a research report on Thursday. They set an “outperform” rating on the stock. Eleven investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $64.75.
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery.
Read More: What are earnings reports?
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.